Your session is about to expire
← Back to Search
Cannabidiol for Obsessive-Compulsive Disorder
Study Summary
This trial will study the safety and effectiveness of a drug called Epidiolex in adults with obsessive-compulsive and related disorders. The drug will be given for two weeks in an open-label fashion, meaning all participants will receive the medication.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 & 3 trial • 90 Patients • NCT04387617Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does the application process for this trial remain open?
"According to clinicaltrials.gov, this trail is actively enlisting volunteers and has been running since April 14th 2022 (with updates up until June 28th)."
Does this experiment accommodate individuals who are 75 and older?
"This study's inclusion criteria mandates that potential participants should be between 18 and 65 years of age. For those younger than 18, there are 287 trials available; for seniors over the age of 65, 733 studies exist."
What potential risks should be considered prior to administering Cannabidiol?
"The safety rating of Cannabidiol was estimated to be 2 on our scale, as this is a Phase 2 trial which has yielded data attesting to its risk profile but not its efficacy."
How many participants are the researchers expecting to recruit for this experiment?
"Indeed, the information available on clinicaltrials.gov demonstrates that this research trial is currently in its recruitment phase. It began being advertised online on April 14th 2022 and has been recently updated as of June 28th 2022. This study requires 15 participants from a single site to be enrolled."
Are there any preceding studies involving the usage of Cannabidiol?
"Currently, 79 trials are underway that focus on Cannabidiol. Of those studies, 16 have moved into Phase 3 of their research process. Despite the majority being based in Ribeirao Preto (Sao Paulo), there are a total of 290 sites working with this drug."
What outcome is this research endeavor aiming to produce?
"The primary goal of this 8-week trial is to evaluate the efficacy of a treatment via changes in NIMH Symptom Severity Scale scores. Secondary objectives include gaugeing patient progress with Clinical Global Impressions- Improvement Scale, Hamilton Depression Rating Scale and Sheehan Disability Scale assessments at each visit."
What criteria must one meet in order to be eligible for the research trial?
"This study is attempting to recruit 15 individuals aged 18-65 that present with Hoarding Disorder. In order to qualify for this trial, the patient must meet certain standards such as being of legal age and exhibiting a Young Brown Obsessive Compulsive Scale score of at least 18 upon initial assessment. Additionally, they must comprehend and agree to the terms outlined in the informed consent document."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What site did they apply to?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger